Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description

Product information

32 evidence topics · 24 sources

Generic, brand name and therapeutic class of product2 evidence topics · 3 sources
Dosage forms and strengths2 evidence topics · 2 sources
Average sales price and wholesale acquisition cost1 evidence topic · 2 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication1 evidence topic · 1 source
Pharmacology8 evidence topics · 9 sources
Contraindications/Warnings/Precautions/Adverse effects5 evidence topics · 4 sources
Special populations1 evidence topic · 1 source
Drug/Drug, drug/disease interactions3 evidence topics · 3 sources
Dosing and administration3 evidence topics · 2 sources
Access and distribution2 evidence topics · 2 sources
Co-prescribed/Concomitant therapies1 evidence topic · 1 source
Effect of Imlifidase on quality measures1 evidence topic · 1 source
Product comparison1 evidence topic · 1 source